JP6850262B2 - 皮膚の抗老化剤及び抗老化組成物 - Google Patents
皮膚の抗老化剤及び抗老化組成物 Download PDFInfo
- Publication number
- JP6850262B2 JP6850262B2 JP2017557765A JP2017557765A JP6850262B2 JP 6850262 B2 JP6850262 B2 JP 6850262B2 JP 2017557765 A JP2017557765 A JP 2017557765A JP 2017557765 A JP2017557765 A JP 2017557765A JP 6850262 B2 JP6850262 B2 JP 6850262B2
- Authority
- JP
- Japan
- Prior art keywords
- inositol
- aging
- skin
- agents
- monosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003712 anti-aging effect Effects 0.000 title claims description 79
- 239000000203 mixture Substances 0.000 title claims description 35
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical class OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 73
- 239000003795 chemical substances by application Substances 0.000 claims description 60
- 229960000367 inositol Drugs 0.000 claims description 50
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 48
- 150000002772 monosaccharides Chemical group 0.000 claims description 46
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 39
- 150000004001 inositols Chemical class 0.000 claims description 36
- 229920001542 oligosaccharide Polymers 0.000 claims description 30
- 150000002482 oligosaccharides Chemical class 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 108010014258 Elastin Proteins 0.000 claims description 18
- 102000016942 Elastin Human genes 0.000 claims description 14
- 229920002549 elastin Polymers 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000037319 collagen production Effects 0.000 claims description 4
- 206010040954 Skin wrinkling Diseases 0.000 description 38
- 230000037303 wrinkles Effects 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 36
- 108010035532 Collagen Proteins 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 230000002500 effect on skin Effects 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- -1 martitol Chemical compound 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002994 raw material Substances 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100274957 Mus musculus Col1a1 gene Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- CDAISMWEOUEBRE-JMVOWJSSSA-N cis-inositol Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-JMVOWJSSSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- CDAISMWEOUEBRE-GNIYUCBRSA-N muco-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-GNIYUCBRSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(1)イノシトールに単糖又はオリゴ糖が結合したイノシトール誘導体であって、イノシトール1分子に結合した前記単糖又は前記オリゴ糖の合計が単糖単位換算で2以上であるイノシトール誘導体を有効成分として含有する、皮膚の抗老化剤。
(2)コラーゲンの産生促進用である、(1)に記載の皮膚の抗老化剤。
(3)エラスチンの産生促進用である、(1)又は(2)に記載の皮膚の抗老化剤。
(4)前記単糖がグルコースである、(1)〜(3)のいずれかに記載の皮膚の抗老化剤。
(5)前記オリゴ糖がグルコースを構成単位として含む、(1)〜(4)のいずれかに記載の皮膚の抗老化剤。
(6)前記イノシトールがmyo−イノシトールである、(1)〜(5)のいずれかに記載の皮膚の抗老化剤。
(7)(1)〜(6)のいずれかに記載の皮膚の抗老化剤及び薬学的に許容される担体を含有する、皮膚の抗老化組成物。
(8)前記皮膚の抗老化剤の含有量が0.01〜50質量%である、(7)に記載の皮膚の抗老化組成物。
(9)皮膚外用剤である、(7)又は(8)に記載の皮膚の抗老化組成物。
(10)化粧料である、(7)〜(9)のいずれかに記載の皮膚の抗老化組成物。
一実施形態において、本発明は、イノシトールに単糖又はオリゴ糖が結合したイノシトール誘導体であって、イノシトール1分子に結合した前記単糖又は前記オリゴ糖の合計が単糖単位換算で2以上であるイノシトール誘導体を有効成分として含有する、皮膚の抗老化剤を提供する。実施例において後述するように、本実施形態の抗老化剤は、表皮性のしわと真皮性のしわの双方に効果を示すことができる。
本実施形態の抗老化剤において、イノシトール誘導体は、イノシトール及び糖が結合したものである。後述するように、イノシトールに結合する糖は、単糖であってもよく、オリゴ糖であってもよい。例えば、1分子のイノシトールに複数の単糖が結合していてもよく、1分子のイノシトールに1又は複数のオリゴ糖が結合していてもよく、1分子のイノシトールに1又は複数の単糖及び1又は複数のオリゴ糖が結合していてもよい。イノシトール誘導体において、1分子のイノシトールに結合した単糖又はオリゴ糖の合計は、単糖単位に換算して2以上であり、例えば3以上であってもよく、例えば4以上であってもよい。
イノシトール誘導体の合成方法としては、特に制限はなく、従来知られている方法で適宜合成することができる。例えば、イノシトール及びオリゴ糖の1種であるシクロデキストリンを、シクロデキストリングルカノトランスフェラーゼの存在下で反応させて、イノシトール誘導体を合成してもよい(例えば、特開昭63−196596号公報を参照。)あるいは、グルコシル亜リン酸エステルを糖供与体として用い、グルコシル体を得る方法により、イノシトール誘導体を合成してもよい(例えば、特開平6−298783号公報を参照)。
一実施形態において、本発明は、上述した抗老化剤及び薬学的に許容される担体を含有する、皮膚の抗老化組成物を提供する。本実施形態の抗老化組成物は、皮膚外用剤であってもよく、化粧料であってもよい。
一実施形態において、本発明は、イノシトールに単糖又はオリゴ糖が結合したイノシトール誘導体であって、イノシトール1分子に結合した前記単糖又は前記オリゴ糖の合計が単糖単位換算で2以上であるイノシトール誘導体を哺乳動物に投与する工程を備える、皮膚のしわの予防又は治療方法を提供する。
(イノシトール誘導体の作製)
myo−イノシトールに、グルコース又はグルコースを単糖単位とする糖を結合させ、参考例1、実施例2〜6及び比較例1のイノシトール誘導体を作製した。各イノシトール誘導体を液体クロマトグラフィー質量分析法(LC−MS)で分析し、myo−イノシトールに結合したグルコースの数が1個、2個、3個、4個以上である分子の割合を質量%で表1に示した。なお、実施例2のイノシトール誘導体において、myo−イノシトールに結合したグルコース鎖のグルコース数が1個である分子の割合は12質量%、2個である分子の割合は30質量%、3個である分子の割合は9質量%、4個である分子の割合は12質量%、5個である分子の割合は2質量%であった。
(繊維芽細胞におけるコラーゲン及びエラスチン発現促進効果の検討)
正常ヒト線維芽細胞におけるコラーゲン及びエラスチンの遺伝子発現を検討した。なお、細胞の老化によりコラーゲン及びエラスチンの発現量が減少し、シワの原因となることが知られている。
(抗老化組成物の作製)
常法に基づき、表3に示す組成で、実施例7及び実施例8の抗老化組成物(ローション)を作製した。イノシトール誘導体としては、上述した実施例2のイノシトール誘導体を使用した。
(抗老化組成物の評価)
同意が得られた健常な成人男女32名のボランティア被験者の腕に、1.5cm×1.5cmの領域を設定した。当該領域に、米粒大の、実施例7〜11、比較例2及び比較例3の抗老化組成物を、1日2回、28日間塗布した。
実施例7〜11、比較例2及び比較例3の抗老化組成物の、被検者の腕への最終塗布後2日目の午前中に、水分蒸散量測定装置(型式「バポスキャンAS−VT100RS」、アサヒテクノラボ社製)を用いて、被検者の腕における、抗老化組成物の塗布領域と非塗布領域の経表皮水分蒸散量(TEWL値)をそれぞれ測定した。
実施例10、実施例11、比較例2及び比較例3の乳液の、被検者の顔面への最終塗布の後に、表7に示す評価基準に基づいて、しわの改善効果を評価した。頬部の表皮性の小じわと目尻の真皮性のしわのそれぞれについての評価を行った。
Claims (7)
- イノシトールにグルコース又はグルコースを構成単位として含むオリゴ糖が結合したイノシトール誘導体であって、イノシトール1分子に結合した前記グルコース又は前記グルコースを構成単位として含むオリゴ糖の合計が単糖単位換算で2以上であるイノシトール誘導体を有効成分として含有し、イノシトールにグルコース又はグルコースを構成単位として含むオリゴ糖が結合したイノシトール誘導体全量に対する、前記有効成分の割合が79質量%以上である、皮膚の抗老化剤。
- コラーゲンの産生促進用である、請求項1に記載の皮膚の抗老化剤。
- エラスチンの産生促進用である、請求項1又は2に記載の皮膚の抗老化剤。
- 前記イノシトールがmyo−イノシトールである、請求項1〜3のいずれか一項に記載の皮膚の抗老化剤。
- 請求項1〜4のいずれか一項に記載の皮膚の抗老化剤及び薬学的に許容される担体を含有する、皮膚の抗老化組成物。
- 皮膚外用剤である、請求項5に記載の皮膚の抗老化組成物。
- 化粧料である、請求項5又は6に記載の皮膚の抗老化組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015250071 | 2015-12-22 | ||
JP2015250071 | 2015-12-22 | ||
PCT/JP2016/082117 WO2017110248A1 (ja) | 2015-12-22 | 2016-10-28 | 皮膚の抗老化剤及び抗老化組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017110248A1 JPWO2017110248A1 (ja) | 2018-10-11 |
JP6850262B2 true JP6850262B2 (ja) | 2021-03-31 |
Family
ID=59090425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017557765A Active JP6850262B2 (ja) | 2015-12-22 | 2016-10-28 | 皮膚の抗老化剤及び抗老化組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10918585B2 (ja) |
EP (1) | EP3395324B1 (ja) |
JP (1) | JP6850262B2 (ja) |
CN (1) | CN108135821A (ja) |
ES (1) | ES2904592T3 (ja) |
WO (1) | WO2017110248A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2018225728A1 (ja) * | 2017-06-05 | 2020-04-02 | 昭和電工株式会社 | グリコサミノグリカン産生促進剤及びグリコサミノグリカン産生促進用組成物 |
JPWO2019045113A1 (ja) * | 2017-09-04 | 2020-08-20 | 昭和電工株式会社 | イノシトール誘導体の混合物 |
WO2020230741A1 (ja) * | 2019-05-13 | 2020-11-19 | 昭和電工株式会社 | がん細胞増殖抑制剤及びがん細胞増殖抑制用組成物 |
EP4197522A1 (en) | 2021-12-20 | 2023-06-21 | Clariant International Ltd | Composition comprising galactinol and use thereof |
CN115137661A (zh) * | 2022-07-07 | 2022-10-04 | 广州品域美妆创新科技有限公司 | 含β-烟酰胺单核苷酸的抗皱组合物及其制备方法、化妆品 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0649715B2 (ja) | 1987-02-10 | 1994-06-29 | 栗田工業株式会社 | 末端にイノシト−ル残基を結合したグルコオリゴ糖およびその製造方法 |
JPH06298783A (ja) | 1993-03-31 | 1994-10-25 | Mitsui Toatsu Chem Inc | 新規なグリコシドの製造法 |
DE19624705A1 (de) | 1996-06-20 | 1998-01-08 | Deutsches Krebsforsch | Dendrimere auf Saccharid-Basis |
JP4624831B2 (ja) * | 2004-03-25 | 2011-02-02 | 昭和電工株式会社 | イノシトール誘導体を含有する皮膚外用剤及び化粧料 |
EP1744725B1 (en) | 2004-03-25 | 2009-07-29 | Showa Denko K.K. | A skin care and cosmetic preparation containing an inositol derivative |
JP2007084484A (ja) * | 2005-09-22 | 2007-04-05 | Api Corporation | 皮膚外用剤 |
JP2008239533A (ja) * | 2007-03-27 | 2008-10-09 | Chikuno Shokuhin Kogyo Kk | 抗炎症剤、保湿剤、皮膚化粧料及び洗浄剤 |
US20110020477A1 (en) | 2008-03-31 | 2011-01-27 | Shiseido Company, Ltd. | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles |
FR2948286B1 (fr) | 2009-07-27 | 2011-08-26 | Jean-Noel Thorel | Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes |
JP2014114289A (ja) | 2013-12-13 | 2014-06-26 | Showa Denko Kk | 化粧料または皮膚外用剤 |
AU2015262386A1 (en) | 2014-05-19 | 2016-12-15 | Suntory Holdings Limited | Novel Uses of Rose Pigment Compounds |
US20170312301A1 (en) | 2014-10-29 | 2017-11-02 | Showa Denko K.K. | Skin barrier function-improving agent and composition for improving skin barrier function |
JPWO2016076310A1 (ja) | 2014-11-10 | 2017-08-17 | 昭和電工株式会社 | 保湿剤 |
-
2016
- 2016-10-28 US US16/061,008 patent/US10918585B2/en active Active
- 2016-10-28 JP JP2017557765A patent/JP6850262B2/ja active Active
- 2016-10-28 ES ES16878146T patent/ES2904592T3/es active Active
- 2016-10-28 CN CN201680059980.XA patent/CN108135821A/zh active Pending
- 2016-10-28 WO PCT/JP2016/082117 patent/WO2017110248A1/ja active Application Filing
- 2016-10-28 EP EP16878146.6A patent/EP3395324B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2904592T3 (es) | 2022-04-05 |
JPWO2017110248A1 (ja) | 2018-10-11 |
EP3395324B1 (en) | 2021-12-08 |
US10918585B2 (en) | 2021-02-16 |
WO2017110248A1 (ja) | 2017-06-29 |
US20180360719A1 (en) | 2018-12-20 |
EP3395324A4 (en) | 2019-08-14 |
EP3395324A1 (en) | 2018-10-31 |
CN108135821A (zh) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6850262B2 (ja) | 皮膚の抗老化剤及び抗老化組成物 | |
KR101154616B1 (ko) | 캄페롤 및 퀘르세틴을 함유하는 히알루론산 생성 촉진용조성물 | |
JP7396418B2 (ja) | イノシトール誘導体の製造方法 | |
JP2012062266A (ja) | 皮膚線維芽細胞のタンパク質産生促進剤および角化細胞遊走・増殖促進剤 | |
JP2019112354A (ja) | 抗炎症剤及び抗炎症用組成物 | |
EP3636266A1 (en) | Agent for inhibiting skin trouble and composition for inhibiting skin trouble | |
US20230355646A1 (en) | Autophagy activator | |
JP5487227B2 (ja) | ヒアルロン酸合成酵素遺伝子の発現促進剤 | |
JPWO2018225728A1 (ja) | グリコサミノグリカン産生促進剤及びグリコサミノグリカン産生促進用組成物 | |
EP4215200A1 (en) | Autophagy activator | |
JP2024114037A (ja) | 表皮角化細胞の角化促進に用いるための剤およびその用途 | |
JP2014074063A (ja) | ヒアルロン酸合成酵素遺伝子の発現促進剤 | |
EP2762130B1 (en) | Promoter for expression of clock gene and hyaluronic acid synthase gene | |
KR20200136737A (ko) | Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물 | |
KR20160064404A (ko) | 파낙시돌을 함유하는 보습용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201015 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210305 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6850262 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |